Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
beta-lactamase inhibitor |
| gptkbp:administeredBy |
ceftazidime-avibactam combination
|
| gptkbp:approvedBy |
2015
complicated urinary tract infections complicated intra-abdominal infections hospital-acquired pneumonia ventilator-associated pneumonia |
| gptkbp:ATCCode |
J01XD56
|
| gptkbp:brand |
Avycaz
Zavicefta |
| gptkbp:CASNumber |
1192491-61-4
|
| gptkbp:chemicalClass |
diazabicyclooctane
|
| gptkbp:combines |
gptkb:aztreonam
gptkb:ceftazidime |
| gptkbp:developedBy |
gptkb:Pfizer
gptkb:Allergan |
| gptkbp:discoveredBy |
gptkb:AstraZeneca
|
| gptkbp:eliminationHalfLife |
2.7 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C7H11N3O6S
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avibactam
|
| gptkbp:indication |
multi-drug resistant Gram-negative infections
|
| gptkbp:legalStatus |
prescription only
patented |
| gptkbp:mechanismOfAction |
inhibits beta-lactamase enzymes
|
| gptkbp:molecularWeight |
265.24 g/mol
|
| gptkbp:notEffectiveAgainst |
Gram-positive bacteria
anaerobic bacteria metallo-beta-lactamases |
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:resistantTo |
mutations in beta-lactamase enzymes
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea anxiety constipation headache insomnia seizures (rare) |
| gptkbp:target |
class A beta-lactamases
class C beta-lactamases some class D beta-lactamases |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:Novexel
|
| gptkbp:bfsLayer |
8
|